 CAMBRIDGE, Mass., Nov. 25, 2020 GLOBE NEWSWIRE -- Surface Oncology Nasdaq: SURF, a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, chief executive officer, and Robert Ross, M.D., chief medical officer, will participate in the upcoming 3rd Annual Evercore ISI Global HealthCONx Conference on December 2, 2020 at 12:10 p.m. ET. The discussion will focus on Surface Oncologys lead programs, SRF617 targeting CD39 and SRF388 targeting IL-27, as well as Surfaces emerging pre-clinical pipeline, highlighted by SRF813 targeting PVRIG, also known as CD112R and SRF114 targeting CCR8. 